PT  - JOURNAL ARTICLE
AU  - Spensley, Katrina
AU  - Gleeson, Sarah
AU  - Martin, Paul
AU  - Thomson, Tina
AU  - Clarke, Candice L.
AU  - Pickard, Graham
AU  - Thomas, David
AU  - McAdoo, Stephen P.
AU  - Randell, Paul
AU  - Kelleher, Peter
AU  - Bedi, Rachna
AU  - Lightstone, Liz
AU  - Prendecki, Maria
AU  - Willicombe, Michelle
TI  - Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in patients receiving haemodialysis
AID  - 10.1101/2022.01.25.22269804
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.25.22269804
4099  - http://medrxiv.org/content/early/2022/01/26/2022.01.25.22269804.short
4100  - http://medrxiv.org/content/early/2022/01/26/2022.01.25.22269804.full
AB  - Background Emerging data suggest a reduction in SARS-CoV-2 vaccine effectiveness against Omicron SARS-CoV-2 infection. There is also evidence to show that Omicron is less pathogenic than previous variants. For clinically vulnerable populations, a less pathogenic variant may still have significant impact on morbidity and mortality. Herein we assess the clinical impact of Omicron infection, and vaccine effectiveness, in an in-centre haemodialysis (IC-HD) population.Methods One thousand, one hundred and twenty-one IC-HD patients were included in the analysis, all patients underwent weekly screening for SARS-CoV-2 infection via RT-PCR testing between 1st December 2021 and 16th January 2022. Screening for infection via weekly RT-PCR testing and 3-monthly serological assessment started prior to the vaccine roll out in 2020.Results Omicron infection was diagnosed in 145/1121 (12.9%) patients over the study period, equating to an infection rate of 3.1 per 1000 patient days. Vaccine effectiveness (VE) against Omicron infection in patients who had received a booster vaccine was 58 (23-75)%, p=0.002; VE was seen in patients who received either ChAdOx1, VE of 47(2-70)%, p=0.034, or BNT162b2, VE of 66 (36-81)%, p=0.0005, as their first two doses. No protection against infection was seen in patients who were partially vaccinated (2-doses), p=0.83. Prior infection was associated with reduced likelihood of Omicron infection, HR 0.69 (0.50-0.96), p=0.0289. Four (2.8%) patients died within 28 days of infection diagnosis, with no excess mortality was seen in patients with infection.Conclusion 3-doses of SARS-CoV-2 vaccines are required in ICHD to provide protection against Omicron infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The authors are also grateful for support from The Nan Diamond Fund, Sidharth and Indira Burman, and the Auchi Charitable Foundation. KS is supported by an NIHR ACF. MP is supported by an NIHR clinical lectureship. Work in DCT's lab is supported by a Wellcome Trust Clinical Career Development FellowshipAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study, sponsored by Imperial College London, was approved by the Health Research Authority, Research Ethics Committee (Reference: 20/WA/0123).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript